| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/22/2023 |
4
| Binder Gwendolyn (See Remarks) has filed a Form 4 on Cabaletta Bio, Inc.|
Txns:
| Sold 10,700 shares
@ $13.4052, valued at
$143.4k
Sold 300 shares
@ $13.8233, valued at
$4.1k
Exercised 11,000 options to buy
@ $1.01, valued at
$11.1k
|
|
| 08/22/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/02/2023 |
4
| Simon Mark (Director) has filed a Form 4 on Cabaletta Bio, Inc.|
Txns:
| Granted 22,000 options to buy
@ $11.18, valued at
$246k
|
|
| 06/02/2023 |
4
| Bollard Catherine (Director) has filed a Form 4 on Cabaletta Bio, Inc.|
Txns:
| Granted 22,000 options to buy
@ $11.18, valued at
$246k
|
|
| 06/02/2023 |
4
| HENRIQUES RICHARD C JR (Director) has filed a Form 4 on Cabaletta Bio, Inc.|
Txns:
| Granted 22,000 options to buy
@ $11.18, valued at
$246k
|
|
| 06/02/2023 |
4
| Brun Scott C. (Director) has filed a Form 4 on Cabaletta Bio, Inc.|
Txns:
| Granted 22,000 options to buy
@ $11.18, valued at
$246k
|
|
| 06/01/2023 |
SC 13G
| Bain Capital Life Sciences Opportunities III, LP reports a 5% stake in Cabaletta Bio, Inc. |
| 06/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/26/2023 |
SC 13G
| Flynn James E reports a 5.9% stake in Cabaletta Bio, Inc. |
| 05/19/2023 |
4
| Binder Gwendolyn (See Remarks) has filed a Form 4 on Cabaletta Bio, Inc.|
Txns:
| Sold 22,000 shares
@ $11.8106, valued at
$259.8k
Exercised 22,000 options to buy
@ $1.01, valued at
$22.2k
|
|
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/16/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
8-K
| Investor presentation |
| 03/16/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|